Seeking Solutions for Brain Tumors
“We’re not in the top ranking among [hospitals conducting] clinical trials, but when you look at enrollment we are at the top of the list,” he says. “We are offering a high volume of cases, and the more you do, the
better you are; like in many disciplines, it relates to better outcomes and
Researching a prospective “tumor vaccine is something we are pursuing,” he says. In developing programs, whether telestroke or brain tumor research, “having clinical focus is absolutely critical,” Pomeroy says.
Funding sources for the Barrow programs include the National Institutes of Health, focusing on areas ranging from basic science research, advanced diagnostics, or therapeutic innovations. “I think increasing our clinical volume will be a substantial indicator of our success,” Pomeroy says.
This article appears in the September 2011 issue of HealthLeaders magazine.
Joe Cantlupe is a senior editor with HealthLeaders Media Online.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Handshaking Spreads Germs. Get Over It.
- Healthcare Costs Start With What We Eat
- Hospitals Likely to Outsource ICD-10 at Launch
- IOM Identifies GME Problems, Calls for Finance Changes
- CMS Confirms ICD-10 Deadline
- Anatomy of 3 Health System Rebranding Efforts
- Premium Subsidy Fight Creating Uncertainty for Hospitals, Health Plans
- 2015 HIX Premium Hikes May Top 7%